225(top 1%)
PR articles
41.9K(top 0.1%)
PR citations
80(top 0.1%)
PR h-index
93(top 0.1%)
h-index
277
documents
66.6K
doc citations
3.6K
citing journals
100
times ranked

Publications

229 peer-reviewed articles • 48,864 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Natural Killer Cell–Mediated Cytotoxicity Shapes the Clonal Evolution of B-cell Leukemia
Cancer Immunology Research, 2025, 13, 430-446
4.22Citations (PDF)
2Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma70.7107Citations (PDF)
3Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Nature Medicine, 2024, 30, 519-530
33.0113Citations (PDF)
4CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool
Cancer Discovery, 2024, 14, 1226-1251
25.137Citations (PDF)
5IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Cancer Discovery, 2024, 14, 1206-1225
25.167Citations (PDF)
6Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening
Nature Biotechnology, 2024, 43, 214-222
29.842Citations (PDF)
7DNA damage induces p53-independent apoptosis through ribosome stalling
Science, 2024, 384, 785-792
36.2142Citations (PDF)
8Gene and protein sequence features augment HLA class I ligand predictions
Cell Reports, 2024, 43, 114325
6.34Citations (PDF)
9ITPK1 Sensitizes Tumor Cells to IgA-dependent Neutrophil Killing In Vivo
Journal of Immunology, 2024, 213, 1244-1254
0.62Citations (PDF)
10Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
Nature Medicine, 2024, 30, 3284-3290
33.0113Citations (PDF)
11Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Nature Medicine, 2024, 30, 3223-3235
33.072Citations (PDF)
12Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system4.96Citations (PDF)
13Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens
Nature Biotechnology, 2023, 41, 783-787
29.843Citations (PDF)
14γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
Nature, 2023, 613, 743-750
37.9294Citations (PDF)
15PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
Nature Cancer, 2023, 4, 535-549
22.539Citations (PDF)
16DRAG in situ barcoding reveals an increased number of HSPCs contributing to myelopoiesis with age13.727Citations (PDF)
17Protocol for ex vivo culture of patient-derived tumor fragments
STAR Protocols, 2023, 4, 102282
1.128Citations (PDF)
18Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment
Cancer Discovery, 2023, 13, 2212-2227
25.142Citations (PDF)
19Safety switches for adoptive cell therapy5.248Citations (PDF)
20Tertiary lymphoid structures in cancer
Science, 2022, 375,
36.21,065Citations (PDF)
21QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment
OncoImmunology, 2022, 11,
5.420Citations (PDF)
22Replicative history marks transcriptional and functional disparity in the CD8+ T cell memory pool
Nature Immunology, 2022, 23, 791-801
23.547Citations (PDF)
23PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
Clinical Cancer Research, 2022, 28, 4893-4906
6.840Citations (PDF)
24Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
Nature Medicine, 2021, 27, 256-263
33.0318Citations (PDF)
25Formation of Tissue-Resident CD8+ T-Cell Memory7.231Citations (PDF)
26Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines5.254Citations (PDF)
27Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy
Cancer Discovery, 2021, 11, 2602-2619
25.1186Citations (PDF)
28Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features13.7118Citations (PDF)
29An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Nature Medicine, 2021, 27, 1250-1261
33.0355Citations (PDF)
30HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial
2021, 9, e002547
15Citations (PDF)
31The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues
Nature Reviews Immunology, 2021, 22, 283-293
53.8207Citations (PDF)
32Single-cell analysis of regions of interest (SCARI) using a photosensitive tag
Nature Chemical Biology, 2021, 17, 1139-1147
11.818Citations (PDF)
33Multimodular Optimization of Chemically Regulated T Cell Switches Demonstrates Flexible and Interchangeable Nature of Immune Cell Signaling Domains
Human Gene Therapy, 2021, 32, 1029-1043
3.23Citations (PDF)
34Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response7.536Citations (PDF)
35Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells
Cell Reports, 2021, 37, 110013
6.377Citations (PDF)
36Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma13.7303Citations (PDF)
37T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
Nature Biotechnology, 2021, 40, 488-498
29.836Citations (PDF)
38Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Nature Medicine, 2020, 26, 1839-1844
33.0393Citations (PDF)
39Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Cell, 2020, 183, 818-834.e13
33.6521Citations (PDF)
40Comprehensive analysis of cutaneous and uveal melanoma liver metastases
2020, 8, e001501
64Citations (PDF)
41Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
2020, 8, e000848
167Citations (PDF)
42A committed tissue-resident memory T cell precursor within the circulating CD8+ effector T cell pool9.3111Citations (PDF)
43A mouse model that is immunologically tolerant to reporter and modifier proteins4.420Citations (PDF)
44CD29 identifies IFN-γ–producing human CD8 + T cells with an increased cytotoxic potential7.5123Citations (PDF)
45Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ
Nature Cancer, 2020, 1, 291-301
22.5144Citations (PDF)
46Quorum Regulation via Nested Antagonistic Feedback Circuits Mediated by the Receptors CD28 and CTLA-4 Confers Robustness to T Cell Population Dynamics
Immunity, 2020, 52, 313-327.e7
22.670Citations (PDF)
47B cells and tertiary lymphoid structures promote immunotherapy response
Nature, 2020, 577, 549-555
37.92,475Citations (PDF)
48Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Nature Medicine, 2020, 26, 566-576
33.01,300Citations (PDF)
49Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells
Cancer Immunology Research, 2020, 8, 685-697
4.218Citations (PDF)
50CD8+ T cell states in human cancer: insights from single-cell analysis
Nature Reviews Cancer, 2020, 20, 218-232
60.71,343Citations (PDF)
51Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
Cell, 2019, 178, 585-599.e15
33.6244Citations (PDF)
52Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Nature, 2019, 572, 538-542
37.9467Citations (PDF)
53Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection13.733Citations (PDF)
54Defining ‘T cell exhaustion’
Nature Reviews Immunology, 2019, 19, 665-674
53.81,530Citations (PDF)
55Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Lancet Oncology, The, 2019, 20, 948-960
27.4502Citations (PDF)
56Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Nature Medicine, 2019, 25, 920-928
33.0840Citations (PDF)
57Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy
Nature Medicine, 2019, 25, 612-619
33.0237Citations (PDF)
58Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity
Cancer Immunology Research, 2019, 7, 670-682
4.262Citations (PDF)
59SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
PLoS ONE, 2019, 14, e0212053
2.346Citations (PDF)
60Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer13.7143Citations (PDF)
61Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma
Cell, 2019, 176, 775-789.e18
33.61,084Citations (PDF)
62Cancer Neoantigens
Annual Review of Immunology, 2019, 37, 173-200
29.4551Citations (PDF)
63Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes
Cell, 2018, 172, 549-563.e16
33.6279Citations (PDF)
64Regulation and Function of the PD-L1 Checkpoint
Immunity, 2018, 48, 434-452
22.62,046Citations (PDF)
65T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide–MHC complexes
Nature Biotechnology, 2018, 36, 1191-1196
29.8102Citations (PDF)
66Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Nature Medicine, 2018, 24, 1655-1661
33.0819Citations (PDF)
67Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
Cell, 2018, 174, 1586-1598.e12
33.61,064Citations (PDF)
68A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Nature Medicine, 2018, 24, 994-1004
33.01,112Citations (PDF)
69Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
Nature Medicine, 2018, 25, 89-94
33.0559Citations (PDF)
70Abstract B54: Dissecting immune cell heterogeneity in human cancer by single-cell RNA-sequencing
2018, ,
0Citations (PDF)
71HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia4.619Citations (PDF)
72Guidelines for the use of flow cytometry and cell sorting in immunological studies *
European Journal of Immunology, 2017, 47, 1584-1797
3.1588Citations (PDF)
73Antigen receptor repertoire profiling from RNA-seq data
Nature Biotechnology, 2017, 35, 908-911
29.8333Citations (PDF)
74Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Nature, 2017, 549, 106-110
37.9665Citations (PDF)
75T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors
Cancer Research, 2017, 77, 658-671
3.832Citations (PDF)
76Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer1.915Citations (PDF)
77BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
Cell Reports, 2016, 16, 263-277
6.377Citations (PDF)
78Preventing tumor escape by targeting a post-proteasomal trimming independent epitope
Journal of Experimental Medicine, 2016, 213, 2333-2348
9.324Citations (PDF)
79Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors
JAMA Oncology, 2016, 2, 1490
14.376Citations (PDF)
80Neoantigens encoded in the cancer genome5.274Citations (PDF)
81Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma34.53,053Citations (PDF)
82Neoantigen landscape dynamics during human melanoma–T cell interactions
Nature, 2016, 536, 91-95
37.9454Citations (PDF)
83Reproducibility of Illumina platform deep sequencing errors allows accurate determination of DNA barcodes in cells
BMC Bioinformatics, 2016, 17,
3.016Citations (PDF)
84T Cell Fate at the Single-Cell Level29.4149Citations (PDF)
85A Traceless Selection: Counter-selection System That Allows Efficient Generation of Transposon and CRISPR-modified T-cell Products5.52Citations (PDF)
86Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines
Gene Therapy, 2015, 22, 560-567
3.519Citations (PDF)
87The Branching Point in Erythro-Myeloid Differentiation
Cell, 2015, 163, 1655-1662
33.6166Citations (PDF)
88Assessing T lymphocyte function and differentiation by genetically encoded reporter systems
Trends in Immunology, 2015, 36, 392-400
10.421Citations (PDF)
89Neoantigens in cancer immunotherapy
Science, 2015, 348, 69-74
36.24,601Citations (PDF)
90Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage
Journal of Immunology, 2015, 195, 4075-4084
0.631Citations (PDF)
91Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor
Molecular Therapy, 2015, 23, 1541-1550
10.2106Citations (PDF)
92Functional heterogeneity of human memory CD4 + T cell clones primed by pathogens or vaccines
Science, 2015, 347, 400-406
36.2345Citations (PDF)
93RNAi-mediated TCR Knockdown Prevents Autoimmunity in Mice Caused by Mixed TCR Dimers Following TCR Gene Transfer
Molecular Therapy, 2014, 22, 1983-1991
10.267Citations (PDF)
94Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition
Cell Reports, 2014, 9, 1375-1386
6.341Citations (PDF)
95TCR repertoires of intratumoral T‐cell subsets
Immunological Reviews, 2014, 257, 72-82
6.461Citations (PDF)
96Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Nature, 2014, 515, 577-581
37.91,947Citations (PDF)
97Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype
Human Gene Therapy Methods, 2014, 25, 277-287
4.063Citations (PDF)
98Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response12.5358Citations (PDF)
99Towards error-free profiling of immune repertoires
Nature Methods, 2014, 11, 653-655
24.6468Citations (PDF)
100Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes7.542Citations (PDF)
101Acquired and intrinsic resistance in cancer immunotherapy
Molecular Oncology, 2014, 8, 1132-1139
4.1187Citations (PDF)
102Cellular barcoding: A technical appraisal
Experimental Hematology, 2014, 42, 598-608
0.482Citations (PDF)
103Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma4.6258Citations (PDF)
104Single cell behavior in T cell differentiation
Trends in Immunology, 2014, 35, 170-177
10.428Citations (PDF)
105Barriers to chimerism after major histocompatibility complex-mismatched stem cell transplantation: A potential role for heterologous immunity
Experimental Hematology, 2014, 42, 753-760
0.42Citations (PDF)
106High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma
Nature Medicine, 2014, 21, 81-85
33.0665Citations (PDF)
107The cancer antigenome
EMBO Journal, 2013, 32, 194-203
7.3224Citations (PDF)
108Signatures of mutational processes in human cancer
Nature, 2013, 500, 415-421
37.99,464Citations (PDF)
109Transposon leads to contamination of clinical pDNA vaccine
Vaccine, 2013, 31, 3274-3280
3.110Citations (PDF)
110Development of a Hypersensitive Periodate‐Cleavable Amino Acid that is Methionine‐ and Disulfide‐Compatible and its Application in MHC Exchange Reagents for T Cell Characterisation
ChemBioChem, 2013, 14, 123-131
2.622Citations (PDF)
111Diverse and heritable lineage imprinting of early hematopoietic progenitors0.41Citations (PDF)
112Diverse and heritable lineage imprinting of early haematopoietic progenitors
Nature, 2013, 496, 229-232
37.9388Citations (PDF)
113Human cancer regression antigens5.240Citations (PDF)
114Pairing of T‐cell receptor chains via emulsion PCR
European Journal of Immunology, 2013, 43, 2507-2515
3.1136Citations (PDF)
115Blockade of TGF-β Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer
Journal of Immunology, 2013, 191, 3232-3239
0.644Citations (PDF)
116Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Journal of Clinical Oncology, 2013, 31, e439-e442
16.9793Citations (PDF)
117Mixed functional characteristics correlating with TCR‐ligand koff‐rate of MHC‐tetramer reactive T cells within the naive T‐cell repertoire
European Journal of Immunology, 2013, 43, 3038-3050
3.132Citations (PDF)
118Discovering naturally processed antigenic determinants that confer protective T cell immunity
Journal of Clinical Investigation, 2013, 123, 1976-1987
10.663Citations (PDF)
119Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission16.9125Citations (PDF)
120TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients
OncoImmunology, 2012, 1, 409-418
5.4189Citations (PDF)
121Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma
OncoImmunology, 2012, 1, 609-617
5.473Citations (PDF)
122Dissection of T-cell Antigen Specificity in Human Melanoma
Cancer Research, 2012, 72, 1642-1650
3.8155Citations (PDF)
123Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression
Blood, 2012, 119, 798-804
5.021Citations (PDF)
124Intravital Microscopy Through an Abdominal Imaging Window Reveals a Pre-Micrometastasis Stage During Liver Metastasis12.5198Citations (PDF)
125Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes
Results in Immunology, 2012, 2, 88-96
3.83Citations (PDF)
126Tissue-resident memory CD8 + T cells continuously patrol skin epithelia to quickly recognize local antigen7.5272Citations (PDF)
127Rational Design of DNA Vaccines for the Induction of Human Papillomavirus Type 16 E6- and E7-Specific Cytotoxic T-Cell Responses
Human Gene Therapy, 2012, 23, 1301-1312
3.239Citations (PDF)
128The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study4.616Citations (PDF)
129Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers
Journal of Autoimmunity, 2011, 37, 151-159
6.669Citations (PDF)
130Characterization of CD8+ T-cell response in acute and resolved hepatitis A virus infection
Journal of Hepatology, 2011, 54, 201-208
4.236Citations (PDF)
131High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations
PLoS ONE, 2011, 6, e22523
2.338Citations (PDF)
132The descent of memory T cells4.037Citations (PDF)
133Combination of targeted therapy and immunotherapy in melanoma4.642Citations (PDF)
134Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E74.332Citations (PDF)
135An Early HIV Mutation within an HLA-B*57-Restricted T Cell Epitope Abrogates Binding to the Killer Inhibitory Receptor 3DL1
Journal of Virology, 2011, 85, 5415-5422
3.661Citations (PDF)
136MHC-based detection of antigen-specific CD8+ T cell responses4.632Citations (PDF)
137RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells4.652Citations (PDF)
138Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity
Journal of Controlled Release, 2010, 141, 234-240
11.070Citations (PDF)
139Technologies for MHC class I immunoproteomics
Journal of Proteomics, 2010, 73, 1945-1953
2.414Citations (PDF)
140Lipopolysaccharide contamination in intradermal DNA vaccination: Toxic impurity or adjuvant?4.89Citations (PDF)
141Apoptosis Threshold Set by Noxa and Mcl-1 after T Cell Activation Regulates Competitive Selection of High-Affinity Clones
Immunity, 2010, 32, 754-765
22.689Citations (PDF)
142Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif
Leukemia, 2010, 24, 1901-1909
7.725Citations (PDF)
143Mapping the life histories of T cells
Nature Reviews Immunology, 2010, 10, 621-631
53.852Citations (PDF)
144One naive T cell, multiple fates in CD8+ T cell differentiation
Journal of Experimental Medicine, 2010, 207, 1235-1246
9.3184Citations (PDF)
145Microbead-Assisted Retroviral Transduction for Clinical Application
Human Gene Therapy, 2010, 21, 1335-1342
3.25Citations (PDF)
146Synthetic vehicles for DNA vaccination3.927Citations (PDF)
147Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Nature Medicine, 2010, 16, 565-570
33.0413Citations (PDF)
148Development of Adoptive Cell Therapy for Cancer: A Clinical Perspective
Human Gene Therapy, 2010, 21, 665-672
3.279Citations (PDF)
149Simultaneous Detection of Circulating Autoreactive CD8+ T-Cells Specific for Different Islet Cell–Associated Epitopes Using Combinatorial MHC Multimers
Diabetes, 2010, 59, 1721-1730
4.2191Citations (PDF)
150Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis7.5205Citations (PDF)
151Optimization of Intradermal Vaccination by DNA Tattooing in Human Skin
Human Gene Therapy, 2009, 20, 181-189
3.256Citations (PDF)
152Preclinical development of T cell receptor gene therapy5.249Citations (PDF)
153TCR transgenes and transgene cassettes for TCR gene therapy: status in 20084.661Citations (PDF)
154Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers
Nature Methods, 2009, 6, 520-526
24.6321Citations (PDF)
155Modular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells15.086Citations (PDF)
156Generation of Peptide MHC Class I Monomers and Multimers Through Ligand Exchange2.552Citations (PDF)
157Class I Major Histocompatibility Complexes Loaded by a Periodate Trigger15.028Citations (PDF)
158UV-Induced Ligand Exchange in MHC Class I Protein Crystals15.041Citations (PDF)
159The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
PLoS ONE, 2009, 4, e6910
2.366Citations (PDF)
160Immunotherapeutic Strategies: The Melanoma Example
Immunotherapy, 2009, 1, 679-690
1.99Citations (PDF)
161Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates
Vaccine, 2008, 26, 3346-3351
3.147Citations (PDF)
162GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial4.047Citations (PDF)
163Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B77.5172Citations (PDF)
164Requirements for Effective Antitumor Responses of TCR Transduced T Cells
Journal of Immunology, 2008, 181, 5128-5136
0.652Citations (PDF)
165Dissecting T cell lineage relationships by cellular barcoding
Journal of Experimental Medicine, 2008, 205, 2309-2318
9.3121Citations (PDF)
166T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model2.369Citations (PDF)
167SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens
Blood, 2008, 112, 814-814
5.05Citations (PDF)
168Selecting highly affine and well-expressed TCRs for gene therapy of melanoma
Blood, 2007, 110, 3564-3572
5.0101Citations (PDF)
169Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease
Blood, 2007, 109, 3830-3838
5.011Citations (PDF)
170Title is missing!
BMC Biotechnology, 2007, 7, 2
2.824Citations (PDF)
171Immunological tumor destruction in a murine melanoma model by targeted LTα independent of secondary lymphoid tissue4.657Citations (PDF)
172Targeting self-antigens through allogeneic TCR gene transfer
Blood, 2006, 108, 870-877
5.069Citations (PDF)
173Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice
Virology, 2006, 352, 157-168
2.357Citations (PDF)
174CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD409.343Citations (PDF)
175Dissection of cytotoxic and helper T cell responses5.516Citations (PDF)
176MHC multimer technology: current status and future prospects5.271Citations (PDF)
177Direct Ex Vivo Detection of HLA-DR3–Restricted Cytomegalovirus- and Mycobacterium tuberculosis–Specific CD4+ T Cells
Human Immunology, 2005, 66, 950-961
1.016Citations (PDF)
178Tumor Rejection Induced by CD70-mediated Quantitative and Qualitative Effects on Effector CD8+ T Cell Formation
Journal of Experimental Medicine, 2004, 199, 1595-1605
9.3143Citations (PDF)
179Generating CTL by HLA transplant
Blood, 2004, 103, 4381-4382
5.02Citations (PDF)
180Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition7.5102Citations (PDF)
181Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice7.5161Citations (PDF)
182Title is missing!
Journal of Immunotherapy, 2003, 26, 1-11
2.356Citations (PDF)
183Specificity and affinity motifs for Grb2 SH2-ligand interactions7.570Citations (PDF)
184Adoptive transfer of T-cell immunity
Trends in Immunology, 2002, 23, 264-269
10.432Citations (PDF)
185Effective Postexposure Treatment of Retrovirus-Induced Disease with Immunostimulatory DNA Containing CpG Motifs
Journal of Virology, 2002, 76, 11397-11404
3.649Citations (PDF)
186In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens
Nature Medicine, 2002, 8, 410-414
33.0285Citations (PDF)
187T-cell-receptor gene therapy
Nature Reviews Immunology, 2002, 2, 512-519
53.8259Citations (PDF)
188Enhanced Immunogenicity of HPV 16 E7 Fusion Proteins in DNA Vaccination
Virology, 2002, 294, 47-59
2.370Citations (PDF)
189CMV-specific CD8pos T lymphocyte differentiation in latent CMV infection
Transplantation Proceedings, 2001, 33, 1802-1803
0.74Citations (PDF)
190Differentiation of CMV-specific CD8POS T lymphocytes in primary CMV infection after renal transplantation0.72Citations (PDF)
191Expression of the Serpin Serine Protease Inhibitor 6 Protects Dendritic Cells from Cytotoxic T Lymphocyte–Induced Apoptosis9.3198Citations (PDF)
192Differentiation of cytomegalovirus-specific CD8+ T cells in healthy and immunosuppressed virus carriers
Blood, 2001, 98, 754-761
5.0194Citations (PDF)
193Circumventing T-cell Tolerance to Tumour Antigens
Biologicals, 2001, 29, 277-283
1.47Citations (PDF)
194Immunotherapy through TCR gene transfer
Nature Immunology, 2001, 2, 957-961
23.5275Citations (PDF)
195Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses9.3978Citations (PDF)
196Low-Avidity Self-Specific T Cells Display a Pronounced Expansion Defect That Can Be Overcome by Altered Peptide Ligands
Journal of Immunology, 2001, 167, 3818-3828
0.640Citations (PDF)
197Tracing and characterization of the low-avidity self-specific T cell repertoire
European Journal of Immunology, 2000, 30, 1458-1468
3.158Citations (PDF)
198CD27 is required for generation and long-term maintenance of T cell immunity
Nature Immunology, 2000, 1, 433-440
23.5748Citations (PDF)
199Changing T cell specificity by retroviral T cell receptor display7.589Citations (PDF)
200Junctional Biases in the Naive TCR Repertoire Control the CTL Response to an Immunodominant Determinant of HSV-1
Immunity, 2000, 12, 547-556
22.649Citations (PDF)
201Selective Expansion of Cross-Reactive Cd8+ Memory T Cells by Viral Variants
Journal of Experimental Medicine, 1999, 190, 1319-1328
9.3110Citations (PDF)
202CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
Nature Medicine, 1999, 5, 774-779
33.0456Citations (PDF)
203Enrichment of an Antigen-Specific T Cell Response by Retrovirally Transduced Human Dendritic Cells
Cellular Immunology, 1999, 195, 10-17
2.566Citations (PDF)
204Systemic T cell expansion during localized viral infection
European Journal of Immunology, 1999, 29, 1168-1174
3.178Citations (PDF)
205Bioactive and nuclease-resistant L-DNA ligand of vasopressin7.5217Citations (PDF)
206In Vitro Radiolabeling of Peptides and Proteins3.312Citations (PDF)
207Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator.9.3216Citations (PDF)
208Are MHC-bound peptides a nuisance for positive selection?
Immunity, 1994, 1, 721-723
22.662Citations (PDF)
209Transporters from H-2b, H-2d, H-2s, H-2k, and H-2g7 (NOD/Lt) haplotype translocate similar sets of peptides.7.544Citations (PDF)
210A soluble, single-chain Kd molecule produced by yeast selects a peptide repertoire indistinguishable from that of cell-surface-associated Kd
European Journal of Immunology, 1993, 23, 1776-1783
3.122Citations (PDF)
211Repertoire-Determining Role of Peptide in the Positive Selection of CD8+ T cells
Immunological Reviews, 1993, 135, 157-182
6.48Citations (PDF)
212TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective
Cell, 1993, 74, 577-584
33.6363Citations (PDF)
213Peptide contributes to the specificity of positive selection of CD8+ T cells in the thymus
Cell, 1993, 73, 1041-1049
33.6265Citations (PDF)
214Incorrect attribution of peptide source
Cell, 1993, 75, 613
33.60Citations (PDF)
215Polymorphisms in pockets of major histocompatibility complex class I molecules influence peptide preference.
Journal of Experimental Medicine, 1993, 177, 1713-1721
9.339Citations (PDF)
216Synthetic peptide libraries in the determination of T cell epitopes and peptide binding specificity of class I molecules
European Journal of Immunology, 1992, 22, 1405-1412
3.136Citations (PDF)
217Preferred size of peptides that bind to H-2 Kb is sequence dependent
European Journal of Immunology, 1992, 22, 1603-1608
3.144Citations (PDF)
218A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product
European Journal of Immunology, 1992, 22, 1651-1654
3.139Citations (PDF)
219Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses
European Journal of Immunology, 1992, 22, 3013-3020
3.151Citations (PDF)
220Assembly and intracellular transport of major histocompatibility complex molecules3.936Citations (PDF)
221Peptide selection by MHC class I molecules
Nature, 1991, 350, 703-706
37.9261Citations (PDF)
222Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses
European Journal of Immunology, 1991, 21, 2963-2970
3.197Citations (PDF)
223Empty MHC class I molecules come out in the cold
Nature, 1990, 346, 476-480
37.9932Citations (PDF)
224Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro
Cell, 1990, 62, 563-567
33.6429Citations (PDF)
225Regulatory role of CD19 molecules in B-cell activation and differentiation
Cellular Immunology, 1989, 118, 368-381
2.560Citations (PDF)
226The Human Cell Atlas
ELife, 0, 6,
0.72,336Citations (PDF)
227Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients
ELife, 0, 4,
0.769Citations (PDF)
228Clinical development of cancer vaccines
Nature Medicine, 0, 32, 828-840
33.09Citations (PDF)
229Social status impacts T-cell responses through synapse strength in the prefrontal cortex
Cell Research, 0, 36, 395-410
12.40Citations (PDF)